Trends in Antimicrobial Resistance of Acinetobacter baumannii Isolates from a Metropolitan Detroit Health System-Reference-Cited by-同舟云学术

Trends in Antimicrobial Resistance of Acinetobacter baumannii Isolates from a Metropolitan Detroit Health System

Published:2010-05 Issue:5 Volume:54 Page:2235-2238
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Reddy Tara¹,Chopra Teena¹,Marchaim Dror¹,Pogue Jason M.²,Alangaden George¹,Salimnia Hossein³,Boikov Dina³,Navon-Venezia Shiri⁴,Akins Robert³,Selman Philip³,Dhar Sorabh¹,Kaye Keith S.¹

Affiliation:

1. Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan

2. Department of Pharmacy Services, Sinai-Grace Hospital, Detroit Medical Center, Wayne State University, Detroit, Michigan

3. Department of Clinical Microbiology, Detroit Medical Center, Detroit, Michigan

4. Division of Epidemiology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Abstract

ABSTRACT A phenotypic and genotypic analysis of Acinetobacter baumannii was conducted from 2003 to 2008 in Detroit, MI. The incidence of A. baumannii increased from 1.7 to 3.7/1,000 patient days during the study period. Susceptibility to ampicillin-sulbactam and imipenem decreased from ∼90% to ∼40%. Genotyping revealed polyclonality, suggesting either emergence of multiple resistant strains or spread of a common genetic element. The sharp rise mandates major multidisciplinary interventions to optimize management of this multidrug-resistant pathogen.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01665-09

Reference28 articles.

1. Abbo, A., Y. Carmeli, S. Navon-Venezia, Y. Siegman-Igra, and M. J. Schwaber. 2007. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur. J. Clin. Microbiol. Infect. Dis.26:793-800.

2. Abbo, A., S. Navon-Venezia, O. Hammer-Muntz, T. Krichali, Y. Siegman-Igra, and Y. Carmeli. 2005. Multidrug-resistant Acinetobacter baumannii. Emerg. Infect. Dis.11:22-29.

3. Bassetti, M., E. Righi, S. Esposito, N. Petrosillo, and L. Nicolini. 2008. Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol.3:649-660.

4. Bou, G., G. Cervero, M. A. Dominguez, C. Quereda, and J. Martinez-Beltran. 2000. PCR-based DNA fingerprinting (REP-PCR, AP-PCR) and pulsed-field gel electrophoresis characterization of a nosocomial outbreak caused by imipenem- and meropenem-resistant Acinetobacter baumannii. Clin. Microbiol. Infect.6:635-643.

5. Casal, M., F. Rodriguez, B. Johnson, E. Garduno, F. Tubau, R. O. de Lejarazu, A. Tenorio, M. J. Gimenez, R. Bartolome, C. Garcia-Rey, L. Aguilar, and N. Garcia-Escribano. 2009. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. J. Antimicrob. Chemother.64:69-72.

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiology and antimicrobial resistance trends of Acinetobacter species in the United Arab Emirates: a retrospective analysis of 12 years of national AMR surveillance data;Frontiers in Public Health;2024-01-04

2. Determining Susceptibility and Potential Mediators of Resistance for the Novel Polymyxin Derivative, SPR206, in Acinetobacter baumannii;Antibiotics;2024-01-04

3. Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections;Annals of Pharmacotherapy;2023-10-10

4. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections;Clinical Infectious Diseases;2023-07-18

5. Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity AgainstAcinetobacterSpecies;Clinical Infectious Diseases;2023-05-01